Status:
WITHDRAWN
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
Lead Sponsor:
University of Hawaii
Conditions:
Metastatic Pancreatic Cancer
ERCC1
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to improve and personalize pancreatic cancer care to deliver the most effective therapy while avoiding unnecessary exposure to potential side effects. Excision repai...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma
- Patients must not have had prior chemotherapy or biologic therapy for metastatic pancreatic cancer
- Prior adjuvant chemotherapy for completely resected disease or chemoradiotherapy for locally advanced disease is allowed but must have been administered \> 6 months prior to registration
- ECOG Performance Status of 0, 1, or 2
- Adequate hematologic, hepatic and renal function
Exclusion
- Pregnant or nursing women
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years
- Patients must not have known brain metastases
- Any other condition that in the opinion of the Investigator may render the patient at excessive risk for treatment complications
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01524575
Start Date
January 1 2012
End Date
January 1 2014
Last Update
September 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Hawaii
Honolulu, Hawaii, United States, 96813